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Multiple epiphyseal dysplasia (MED) is a relatively common skeletal dysplasia that can present in childhood
with a variable phenotype of short stature and pain and stiffness in the large joints, and often progresses to early-
onset osteoarthritis in adulthood. Mutations in the matrilin-3 gene (MATN3) have recently been shown to
underlie some forms of autosomal dominant MED. To date all MED mutations in matrilin-3 cluster in the single
A-domain, suggesting that they may disrupt the structure and/or function of this important domain. To
determine the effects of MATN3 mutations on the structure and function of matrilin-3 we expressed both
normal and mutant matrilin-3 in mammalian cells. Wild-type (wt) matrilin-3 was efficiently secreted into
conditioned medium, whereas mutant matrilin-3 was retained and accumulated within the cell. Furthermore,
when the mutant A-domains were examined individually, they existed primarily in an unfolded conformation.
Co-immunoprecipitation experiments demonstrated that the mutant A-domains were specifically associated
with ERp72, a chaperone protein known to be involved in mediating disulfide bond formation. Light microscopy
of cartilage from an MED patient with a MATN3 mutation showed the presence of intracellular material within
the chondrocytes, whilst the overall matrix appeared normal. On electron micrographs, the inclusions noted at
the light microscopy level appeared to be dilated cisternae of rough endoplasmic reticulum and
immunohistochemical analysis confirmed that the retained protein was matrilin-3. In summary, the data
presented in this paper suggest that MED caused by MATN3 mutations is the result of an intracellular retention
of the mutant protein. Hum Mutat 26(6), 557–565, 2005. r r 2005 Wiley-Liss, Inc.
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INTRODUCTION
Extracellular matrix (ECM) proteins typically comprise several
different structural domains that often occur in multiples
[Hohenester and Engel, 2002]. In some instances the same
domain can be found in many different proteins, each of which has
a distinct function. One such protein domain is the von
Willebrand factor A-domain (vWFA) [Whittaker and Hynes,
2002]. This domain was originally identified in von Willebrand
factor, a soluble plasma protein that plays a role in blood clotting
by mediating platelet adhesion to the collagen fibrils of damaged
blood vessels. Von Willebrand factor A-domains (A-domains) are
also found in collagen types VI, type VII, type XII, type XIV, type
XVII, type XX, type XXI, and other ECM proteins such as
matrilins 1–4, cochlin, vitrin, and WARP [Fitzgerald et al., 2002;
Wagener et al., 2005; Whittaker and Hynes, 2002]. A homologue
of the A-domain is the integrin inserted-domain or I-domain,
which is found in many a and all b integrins [Dickeson and
Santoro, 1998].
The A-domain consists of approximately 200 amino acids
arranged in a Rossman or dinucleotide-binding fold, with five
parallel b-strands and one antiparallel b-strand at the center of the
domain surrounded by seven a-helices on the external faces of the
domain [Whittaker and Hynes, 2002]. Many A-domains can
coordinate a metal ion using noncontiguous residues at the top of
the domain called the metal ion-dependent adhesion site
(MIDAS) motif.
A number of human diseases are caused by the mutation of
residues within the A-domains of various proteins. A missense
mutation (p.Gly1679Glu) in the A-domain of the a3 chain of type
VI collagen was found in patients with Bethlem myopathy (MIM]
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reduced secretion and increased degradation of mutant a3(VI)
chains [Sasaki et al., 2000]. Furthermore, a missense mutation in
the A3 domain of von Willebrand factor results in reduced
collagen binding by the mutant protein and an inherited
hemorrhagic syndrome, while the mutant monomers were still
able to assemble into multimers and bind glycoprotein 1b [Ribba
et al., 2001]. Overall, these data suggest that the type and location
of a particular mutation within the A-domain determine the
specific disease mechanism and ultimately the phenotypic
consequence.
Multiple epiphyseal dysplasia (MED) is a skeletal dysplasia of
varying severity and is characterized by stiffness and pain in the
large joints, which often results in early-onset osteoarthritis [Briggs
and Chapman, 2002; Unger and Hecht, 2001]. Several genes have
been implicated in autosomal dominant MED, including those
encoding cartilage oligomeric matrix protein (COMP; MIM]
132400) [Briggs et al., 1995], all three a-chains of type IX collagen
(COL9A1, COL9A2, and COL9A3; MIM] 120210, 600204, and
600969, respectively) [Czarny-Ratajczak et al., 2001; Muragaki
et al., 1996; Paassilta et al., 1999] and matrilin-3 (MATN3; MIM]
607078) [Chapman et al., 2001].
Matrilin-3 is a modular protein found specifically in the ECM of
cartilage [Wagener et al., 1997]. It comprises a single A-domain,
four EGF repeats, and a coiled-coil domain that facilitates
oligomerization. It is the third member of the matrilin family of
proteins, and forms either homotetramers or heterotetramers with
matrilin-1 [Wu and Eyre, 1998; Klatt et al., 2000]. Matrilin-3/1
isolated from cartilage has been shown to bind with high affinity to
both COMP and type IX collagen [Briggs and Chapman, 2002;
Mann et al., 2004].
The gene encoding matrilin-3 (MATN3) is located on
chromosome 2 and comprises eight exons [Belluoccio et al.,
1998]. Several missense mutations in MATN3 have been
associated with MED, including p.Arg121Trp, p.Val194Asp
[Chapman et al., 2001], p.Thr120Met, p.Glu134Lys, p.Ile192Asn,
and p.Ala219Asp [Jackson et al., 2004]. In addition, we also
identified a nonsynonymous polymorphism, p.Glu252Lys [Jackson
et al., 2004], which apparently does not cause MED but may play a
role in modifying disease severity in some patients. All of these
missense mutations and the polymorphism are found in the single
A-domain of matrilin-3, which is encoded by exon 2 of MATN3.
Interestingly, a form of hand osteoarthritis (MIM] 607850) has
been linked to a p.Thr303Met mutation located in the first EGF
repeat of matrilin-3 [Stefansson et al., 2003], while a recessive
form of spondyloepimetaphyseal dysplasia (MIM] 608728) results
from homozygosity for a mutation (p.Cys304Ser) at the neighbor-
ing residue [Borochowitz et al., 2004].
To understand the effect of MED-causing mutations on the
structure and function of matrilin-3 and thereby gain insight into
the disease mechanisms of this form of MED, we expressed both
normal and mutant full-length matrilin-3 proteins and single
A-domains in mammalian cells. This approach allowed us to
investigate the effects of mutations on the folding and trafficking
of matrilin-3 and propose a potential disease mechanism for this
form of MED.
MATERIALSANDMETHODS
Cloning of Normal and Mutant Matrilin-3 A-Domains
PCR amplification of exon 2 of MATN3, which encoded the
entire A-domain, was performed using primers MATN3ex2F
(50-ggcccagccggcctgcaagagcagacccttggac-30, Sfi I restriction site
underlined) and MATN3ex2R (50-gcggccgcacagaaggtttcctggaatct-
30, Not I restriction site underlined) using a standard protocol.
Genomic DNA from MED patients with MATN3 mutations
(p.Arg121Trp, p.Val194Asp, p.Thr120Met, p.Glu134Lys,
p.Ile192Asn, and p.Ala219Asp) and the nonsynonymous poly-
morphism (p.Glu252Lys) was used as the template in the PCR. In
brief, PCR amplifications were performed in 25ml reactions
containing 0.5mM of each primer, 0.625 U of Taq DNA
polymerase, 67mM Tris-HCl (pH 8.0 at 251C), 16mM
(NH4)2SO4, 3.7mM MgCl2, 0.085mg/ml BSA, 6.7mM EDTA,
0.75mM of each dNTP , and 50–100ng of genomic DNA. PCR
cycling consisted of initial denaturation at 951C for 3 min followed
by 35 cycles of 951C for 1 min, 621C for 1min, and 721C for 1min
and a final extension at 721C for5 min. PCR amplified DNA
fragments were purified using the QIAquick
s PCR purification kit
(Qiagen Ltd., Crawley, West Sussex; www1.qiagen.com) and
individual alleles were cloned using the TA cloning kit (Invitrogen
Ltd., Paisley, UK; www.invitrogen.com) following the manufac-
turer’s instructions. Clones containing only the nucleotide change
of interest, as identified by bi-directional DNA sequencing,
underwent double restriction digest with Sfi I and Not I and were
sub-cloned into pSecTag2A (Invitrogen).
Cloning of Normal and Mutant Full-Length Matrilin-3
Human full-length matrilin-3 cDNA (a kind gift from D.
Krakow) was digested with Pst I and subcloned into the pCMV-
TAG4 (Stratagene, La Jolla, CA; www.stratagene.com) vector
(FLM3-CMV). PCR amplification to remove the stop codon was
then performed using M3XbaF (50-ctttcctctagattccaggaa-30, Xba I
restriction site underlined) and M3R (50-aagcttacgatgtatttgtccat
attc-30, Hind III restriction site underlined) using a standard
protocol with Pfu DNA polymerase. The PCR amplified DNA
fragment was purified using the QIAquick
s PCR purification kit
(Qiagen) and then double digested with Xba I and Hind III. The
digested fragment replaced the original Xba I/Hind III fragment in
FLM3-CMV to create WT-FLM3 (wt full-length matrilin-3) with
no stop codon and in-frame with the FLAG tag. p.Val194Asp and
p.Glu252Lys mutations were introduced by replacing a Eco NI/Xba
I fragment from WT-FLM3 with Eco NI/Xba I fragments from the
respective mutant A-domains (see previous) using standard
protocols. All clones were sequenced to confirm that they
contained only the desired mutation.
Cell Culture andTransfection
CHO-B2 cells were cultured in Ham’s F12 media supplemented
with 10% FBS, 2mM L-glutamine, 100U/ml penicillin, and
100mg/ml streptomycin (Biowhittaker; www.bioresearchonline.
com). The cells were incubated at 371C in humidified air
containing 5% CO2.
The cells were transfected using Lipofectin (Invitrogen)
according to the manufacturer’s instructions. Briefly, when the
cells were 50–70% confluent monolayers in 75 cm
2 flasks they
were incubated with 2mg of construct DNA and Lipofectin in
Opti-MEM serum-free media (Invitrogen) for 24 hr. To obtain
stable cell lines the cells were transferred to media containing
250mg/ml Zeocin (Invitrogen) for selection. This media was
changed every 2–3 days until distinct foci of individual clones
resistant to Zeocin could be seen (after  2 weeks). Individual
clones were removed by incubation with trypsin, expanded in
6-well plates and when confluent transferred into 25cm
2 flasks.
Conditioned media and cell lysates were tested for expression
of the A-domain and individual cell lines that expressed the
558 HUMAN MUTATION 26(6), 557^565, 2005A-domain to the highest extent were then used in subsequent
experiments.
SDS-PAGE andWestern Blot Analysis
Cells were lysed by incubation in 500ml RIPA lysis buffer
(10mM Tris, pH 7.4, 150mM NaCl, 1% sodium deoxycholate,
0.1% SDS) on ice for 15 min. The cell monolayer was removed,
centrifuged at 13,600 g for 5min and the supernatant was
removed for analysis. Conditioned media and cell lysates were
separated by SDS-PAGE on 4–12% Tris-Bis gels (Invitrogen).
Proteins were transferred to nitrocellulose membranes and the
recombinant A–domain was detected using an anti-c-myc
monoclonal antibody, clone 9E10 (Roche Diagnostics Ltd. Lewes,
East Sussex, UK; www.roche-applied-science.com) with anti-
mouse HRP conjugate (Sigma-Aldrich Company Ltd., Gillingham,
Dorset, UK; www.sigmaaldrich.com) as a secondary antibody.
Protein bands were visualised with SuperSignal
s West Dura
extended duration substrate (Perbio; www.perbio.com).
Co-immunoprecipitationWith ChaperoneAntibodies
Co-immunoprecipitation was carried out on cell lysates
produced as above from 5 10
5 cells transfected with the different
A-domain constructs. Proteins were precipitated using antibodies
against chaperones found in the rough endoplasmic reticulum
(rER): PDI, ERp72 (Stressgen, San Diego, CA; www.stressgen.
com/), Grp78, Grp94 (Santa Cruz Biotechnology, Santa Cruz, CA;
www.scbt.com). Prior to immunoprecipitation, the cells were cross
linked with dithiobis[succinimidyl propionate] (DSP) to stabilize
protein complexes. Aliquots of cells were washed twice in PBS
then resuspended in 250ml PBS. DSP was added to 1mM from a
fresh stock made up in dry DMSO and incubated for 30 min at
room temperature. To stop the cross-linking reaction, 10mlo f1M
Tris-HCl, pH 7.4 was added and cells were incubated for a further
15 min. Finally, cells were washed twice in PBS and lysed with
RIPA lysis buffer as described above ready for immunoprecipitation.
Lysates were diluted 10-fold with immunoprecipitation buffer
(50mM Tris-HCl, pH 7.4, 1% Triton X-100, 150mM NaCl, 2mM
EDTA). First, cell lysates were precleared by incubation with
0.25mg rabbit IgG (goat IgG with anti-Grp78 and -Grp94) and
20ml Protein A-agarose (Protein G PLUS-agarose with anti-Grp78
and -Grp94) (Santa Cruz Biotechnology) under rotation for 1hr at
41C. The mixture was centrifuged at 3,000 g for 5 min to remove
the beads and nonspecifically bound proteins. The appropriate
chaperone antibody was added to the supernatant and incubated
under rotation for 1hr at 41C. Then 20ml of Protein A-agarose
was added and the tubes were rotated at 41C overnight. After
overnight incubation, the tubes were centrifuged at 3,000 g for
3 min and the supernatant was discarded. The pellet was washed
and centrifuged three times in immunoprecipitation buffer. The
final pellet was resuspended in 1 SDS-PAGE loading buffer
containing 100mM dithiothreitol (DTT), heated at 1001C for
5 min and centrifuged at 6,000 g for 30 sec. The supernatants
were analyzed by Western blotting as described previously.
Immunohistochemistry
An iliac crest biopsy from a patient with the p.Arg121Trp MED-
causing mutation was stained using an anti-matrilin-3 antibody.
Frozen sections (5–10mm thick) were cut from the biopsy and
mounted on superfrost slides. A Vectastain ABC (Rabbit IgG) kit
(Vector Laboratories Ltd., Peterborough, UK; www.vectorlabs.
com) was used according to manufacturer’s instructions. Antibody
staining was detected with a DAB peroxidase substrate kit (Vector
Laboratories Ltd.) and counterstained with hemotoxylin.
RESULTS
MEDMutations Cluster in theA-Domain of Matrilin-3
Missense mutations in the gene encoding matrilin-3 cause an
autosomal dominant form of MED and in total eleven different
mutations have now been identified in 26 unrelated families with
various forms of MED (see Table 1). All but one of these
mutations affect residues comprising the b-strands of the
A-domain; indeed, disease-causing mutations have now been
identified in four of the six b-strands (bB, bC, bD, and bE) that
comprise the single b-sheet. The most common mutation is
p.Arg121Trp, which has been identified in approximately one-
third of all MED patients with a MATN3 mutation (9/26).
Sufficient studies have now been performed to suggest that MED
mutations in MATN3 are predominantly located in exon 2, which
encodes the single A-domain.
TABLE 1. Mutations Identi¢edinMATN3 in 26 Familieswith MED
Nucleotide
change
Predicted
amino acid
change
Location
withinthe
A-domain
Numberof families inwhich thismutation has beenidenti¢ed
Present
study
Previous
studies Reference
c.314T4Cp . P h e 1 0 5 S e r a1 1 Mabuchi et al. [2004]
c.359C4Tp . T h r 1 2 0 M e t b2 4 Jacksonet al. [2004]; Mabuchi et al. [2004]
c.361C4Tp . A r g 1 2 1 T r p bB 2 7 Chapmanet al. [2001]; Jacksonet al. [2004];
Mabuchi et al. [2004];thisstudy
c.368C4A p.Ala123Lys bB 1 Mabuchi et al. [2004]
c.382G4Cp . A l a 1 2 8 P r o bB 1 Mostertet al. [2003]
c.400G4Ap . G l u 1 3 4 L y s bC 1 Jacksonet al. [2004]
c.575T4A p.Ile192Asn bD 1 Jacksonet al. [2004]
c.581A4T p. Val194Asp bD 1 Chapmanet al. [2001]
c.584C4Ap . T h r 1 9 5 L y s bD 1 Thisstudy
c.652T4A p.Tyr218Asn bD 1 Thisstudy
c.656C4A p.Ala219Asp bE 1 Jacksonet al. [2004]
c.754G4Ap . G l u 2 5 2 L y s
a a7 1 3 Jacksonet al. [2004];thisstudy
Matrilin-3 cDNAaccessionnumberinGenBankisNM^002381.3 andnucleotidenumberingisfromthestartoftranslation (i.e.,11correspondstotheA
of theATG translation initiationcodon in the reference sequence). Nucleotide mutations are based on the cDNA sequence ofMATN3 and are preceded
with a‘‘c.’’symbol before the number.
aA non-disease-causingpolymorphism identi¢ed inuna¡ected family members andunrelatedcontrols.
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To determine the effect of MED mutations on the secretion of
matrilin-3 we cloned and expressed in mammalian cells full-length
wt matrilin-3 and matrilin-3 harboring a MED mutation
(p.Val194Asp) and non-synonymous polymorphism (p.Glu252Lys).
SDS-PAGE and Western blot analysis of proteins from the cell
media showed the presence of wt and p.Glu252Lys proteins at the
expected molecular weight of  51 kDa , but not the p.Val194Asp
protein (Fig. 1A). In contrast SDS-PAGE and Western blot
analysis of proteins isolated from the cell lysate showed the
presence of matrilin-3 containing the p.Val194Asp mutation
(Fig. 1B), but not the wt and p.Glu252Lys proteins (other than
at normal background levels expected for a cell expressing high
levels of a recombinant protein).
These data therefore suggested that the p.Val194Asp mutation
prevented the proper trafficking and secretion of matrilin-3,
whereas as the p.Glu252Lys polymorphism did not.
MEDMutations Disrupt the Folding of the
Matrilin-3 A-Domain
The apparent clustering of the majority of MED mutations in
the b-sheet led us to hypothesize that these substitutions were
disrupting the folding of the A-domain of matrilin-3 (Table 1).
Therefore, to determine the precise effect of these disease-causing
mutations we expressed both normal and mutant A-domain
proteins. We chose to express a number of MED mutations
(p.Arg121Trp, p.Val194Asp, p.Thr120Met, p.Glu134Lys, p.Ile192Asn
and p.Ala219Asp) in addition to the non-synonymous polymorph-
ism (p.Glu252Lys).
Following SDS-PAGE and Western blot analysis of conditioned
media from cell lines stably transfected with the wt A-domain
construct a protein band was detected at approximately 25 kDa
(Fig. 1C). This agrees with the predicted molecular weight of the
A-domain (24.2 kDa including c-myc and His6 tags) and no
multimers were observed in samples analyzed without DTT (data
not shown).
SDS-PAGE and Western blot analysis of conditioned media and
cell lysates from clones transfected with constructs containing
the p.Arg121Trp, p.Val194Asp, p.Thr120Met, p.Glu134Lys,
p.Ile192Asn and p.Ala219Asp mutations revealed that condi-
tioned media contained no detectable A-domain (Fig. 1C).
Instead the recombinant A-domain was detected in the cell
lysates, suggesting that the mutant A-domains were not secreted
but retained within the cell. In contrast, in those cells transfected
with an expression vector containing the non-synonymous
polymorphism (p.Glu252Lys), A-domain protein was detected in
conditioned media (Fig. 1C), suggesting that the A-domain was
secreted normally when it contained this non-disease-causing
polymorphism. These data were therefore in agreement with those
obtained for full-length matrilin-3 constructs.
Retained Mutant A-Domains Are Primarily Unfolded
SDS-PAGE and Western blot analysis of the wt A-domain
showed that it migrated faster under non-reducing conditions,
suggesting that the A-domain is smaller and more compact when
the disulfide bond is intact (compare lanes 2 and 3 in Fig. 2A).
This quantifiable characteristic of the recombinant A-domain
therefore allowed us to study the disulfide bonded (‘‘folded’’) state
FIGURE 1. SDS-PAGE and Western blot analysis of conditioned media and cell lysates from CHO cells stably transfected with full-
length matrilin-3 (A and B) and singleA-domain (C) constructs. Gels were run under reducing conditions, and molecular weights
are shown in kDa. A and B: Media and cell lysate samples from cells expressing full-length wt, a MED mutation (pVal194Asp), and
the polymorphism (pGlu252Lys) are shown. Proteins were detected with an anti-FLAG antibody, and the full-length protein is indi-
catedwithanarrowhead.C:Untransfectedcells (C) andcellstransfectedwith normal (wt) andpolymorphic (pGlu252Lys) A-domain
are shown.The A-domain missense mutations shown are pArg121Trp, p. Val194Asp, p.Ile192Asn, pGlu134Lys, p.Ala219Asp, and
p.Thr120Met. Proteinsweredetectedwith an anti-c-myc antibody, and theA-domainisindicatedwith an arrowhead.
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conditioned media, all of the wt A-domain, and also A-domain
containing the non-synonymous polymorphism (p.Glu252Lys) ran
as a faster migrating, disulfide bonded protein under non-reducing
conditions (Lanes marked ‘‘–’’ in Fig. 2A). However, SDS-PAGE
and Western blot analysis of lysates from cells transfected with wt
or p.Glu252Lys A-domain revealed that non-reduced samples
contained a mixture of both forms of A-domain in approximately
equal quantities (Fig. 2B; lanes 2 and 3), which is characteristic of
a cell expressing high levels of recombinant protein that is actively
being folded and secreted.
On the other hand, when cell lysates from cells transfected with
the mutant A-domains (p.Val194Asp, p.Ala219Asp, p.Arg121Trp)
were analyzed by SDS-PAGE and Western blotting, the distribu-
tion of folded and unfolded A-domain was different to that of the
wt A-domain (Fig. 2B; lanes 4–6). Mutant A-domains analyzed
under non-reducing conditions appeared principally as the
non-disulfide bonded and extended form ( 90%), with only a
small proportion of the sample in the more compact form with the
disulfide bond intact ( 10%), suggesting that the folding is either
delayed or incomplete due to these mutations. In addition,
disulfide bonded dimers of around 50 kDa and small quantities of
trimers of around 75 kDa could also be observed (data not shown).
These aggregates were not observed with either the wt or
p.Glu252Lys A-domain proteins.
Retained Mutant A-Domains AssociateWith the
Chaperone ERp72
Since mutant A-domain was retained within the cell lysate and
appeared incorrectly folded (i.e., probably without an intrachain
disulfide bond); we examined the role that specific chaperone
proteins may play in this process. Co-immunoprecipitation with
various anti-chaperone protein antibodies was therefore used to
identify putative interactions with the wt, polymorphic (p.Glu252Lys)
and mutant A-domains (p.Val194Asp, p.Arg121Trp and p.Ala219Asp).
SDS-PAGE and Western blot analysis of total cell extracts
revealed equivalent amounts of ERp72, PDI, Grp78 and Grp94 in
all five cell lines (data not shown). However co-immunoprecipita-
tion of the cell lysates with the anti-ERp72 antibody followed by
SDS-PAGE and Western blot analysis of the immunoprecipitates
showed that only the mutant A-domains co-precipitated with
ERp72, whereas the wt or p.Glu252Lys A-domain did not
(Fig. 3A). Immunoprecipitation experiments in the absence of
FIGURE 2. SDS-PAGE andWestern blot analysis of conditioned media (A) andcell lysates (B) fromCHOcells stably transfectedwith
A-domain constructs under reducing (1) and non-reducing (^) conditions. Samples from cells expressing a normal A-domain con-
struct (wt), apolymorphicconstruct (p.Glu252Lys), andconstructswith thep. Val194Asp, p.Ala219Asp, andp.Arg121Trpmutations
are shown. Samples from untransfected cells were used as a control (C).The recombinant protein was detected using an anti-c-myc
antibody, andmolecularweights areshownin kDa.
FIGURE 3. A: ERp72 was immunoprecipitated from the cell
lysates of recombinant cells, and the immunoprecipitates were
analyzed byWestern blot.The c-myc antibody detected recombi-
nant A-domain in the R121W and A219D immunoprecipitates
and to a lesserextent in theV194D immunoprecipitate. No band
was detectable in the normal (wt), polymorphic (E252K), or
control (C) lanes. B: Immunoprecipitation in the absence of
anti-ERp72 antibody wasperformed as a control for nonspeci¢c
bindingtotheProteinA-agarosebeads.UntransfectedCHOcells
wereused as thecontrol (C).
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caused by non-specific binding of the A-domains to the agarose
beads (Fig. 3B). Coimmunoprecipitation with antibodies to other
chaperone proteins did not identify any specific interactions with
mutant A-domains (data not shown).
Mutant Matrilin-3 is Retained in the Rough
Endoplasmic Reticulum InVivo
Hyaline cartilage from an iliac crest biopsy of a patient with the
p.Arg121Trp mutation was analyzed using light and electron
microscopy. In light micrographs the cartilage as a whole appeared
normal following standard hematoxylin and eosin (H&E) staining
(Fig. 4A). The cells have a normal chondrocyte morphology (i.e.
rounded) and are distributed evenly throughout the extracellular
matrix, which stains homogeneously [Morris et al., 2002].
However, at higher magnification the cytoplasm of the chondro-
cytes showed putative inclusions, which appeared to contain
proteinaceous material (Fig. 4B). Immunohistochemical staining of
this cartilage using an anti-matrilin-3 antibody confirmed that the
retained material was matrilin-3 (Fig. 4C), which did not appear
in the cytoplasm of chondrocytes of an age matched control
(Fig. 4D). The resolution of these images was not sufficient to
pinpoint the intracellular location of matrilin-3.
On electron micrographs, the inclusions noted at the light
microscopy level appeared to be dilated cisternae of rough
endoplasmic reticulum that contained flocculent electron dense
material (Fig. 4E and F), which were not present in control
chondrocytes (Fig. 4G). In addition there were numerous
phagolysosomes within the chondrocytes but the Golgi was within
normal limits. For comparison a chondrocyte from a pseudoachon-
droplasia patient with a COMP mutation is also shown (Fig. 4H).
In summary therefore the chondrocytes appeared to have a normal
morphology but with cytoplasmic inclusions that contained
matrilin-3. Overall these in vivo findings confirm the in vitro
expression data and suggest that misfolding of the A-domain
results in the retention of matrilin-3 within the rER of
chondrocytes.
DISCUSSION
The multiple epiphyseal dysplasias are a relatively common and
genetically heterogeneous group of inherited bone diseases and to
date disease-causing mutations have been identified in six
different genes, the products of which are important for cartilage
structure and function [Briggs and Chapman, 2002; Unger and
Hecht, 2001]. Autosomal dominant MED can result from
mutations in the genes encoding cartilage oligomeric matrix
protein (COMP), type IX collagen (COL9A1, COL9A2 and
COL9A3) and most recently matrilin-3 (MATN3) [Briggs and
Chapman, 2002; Unger and Hecht, 2001]. In addition, an
autosomal-recessive form of MED can result from mutations in
the sulfate transporter 26A2 (SLC26A2/DTDST) [Ballhausen
FIGURE 4. Light andelectronmicrographs ofcartilagefromtheiliac crest biopsy of a14-year-oldpatientwith thep.Arg121Trp muta-
tion. A: H&E staining of hyaline cartilage showing a normal matrix at  10 magni¢cation. B: Magni¢cation (  100) of the same
section of cartilage showing a chondrocyte with apparent staining of the cytoplasm suggesting the presence of protein material,
which is distinct from the nucleus (dark blue). C: Immunohistochemistry of the cartilage showing that the protein retained in the
patient’s chondrocyte stains with an antibody to matrilin-3 (brown),whereas there appears to be no intracellular staining for matri-
lin-3 in the chondrocyte of an aged matched control sample (D) (the cell nucleus is stained blue by DAPI). E and F: Electron micro-
graphs of the patients chondrocytes showing that the rough endoplasmic reticulum cisternae are swollenwith accumulated protein
that has agranularappearance,whencomparedtoacontrolchondrocyte (G). Forcomparisonanelectronmicrographofachondro-
cyte from a pseudoachondroplasia patient with a COMP mutation (p.Gly465Ser) is also shown and in this case the enlarged rER
completely occupies the cytoplasm (H). rER: rough endoplasmic reticulum; N: nucleus. [Color ¢gure can be viewed in the online
issue,whichis available at www.interscience.wiley.com.]
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progress has been made in understanding the disease mechanisms
of MED caused by mutations in COMP [Unger and Hecht, 2001]
and SLC26A2 [Forlino et al., 2005; Rossi and Superti-Furga,
2001], virtually nothing is known about the disease mechanisms of
MED caused by mutations in MATN3. The aim of this study
therefore was to determine the molecular cell pathology of MED
caused by MATN3 mutations.
All of the MED mutations in MATN3 are missense mutations
found in exon 2, which encodes the single A-domain of matrilin-3
[Chapman et al., 2001; Jackson et al., 2004; Mabuchi et al., 2004;
Mostert et al., 2003]. To study the effect of these mutations on the
secretion of matrilin-3 we cloned and expressed full-length wt,
mutant (p.Val194Asp) and polymorphic (p.Glu252Lys) matrilin-3
in mammalian cells. Both the wt and p.Glu252Lys proteins were
efficiently secreted, whereas the p.Val194Asp protein was retained
in the cell lysate, suggesting that the mutation disrupts the
secretion of the abnormal protein. These data are similar to those
obtained for COMP mutations [Hecht et al., 2005] and suggest a
common disease mechanism for this bone dysplasia family.
Most of the MED mutations in MATN3 affect conserved
residues in one of the six b-strands (bA-bF) that together
comprise the b-sheet of the A-domain [Jackson et al., 2004]. This
precise grouping of MED mutations in the b-sheet led to us to
hypothesize that they might disrupt the folding of this structurally
important domain. To investigate this observation further we
expressed individual A-domains; either wt or containing a disease-
causing mutation (p.Thr120Met, p.Arg121Trp, p.Glu134Lys,
p.Ile192Asn, p.Val194Asp and p.Ala219Asp) or non-synonymous
polymorphism (p.Glu252Lys). Normal A-domain was expressed
and secreted from mammalian cells as a disulfide bonded
monomer, demonstrating that this domain can fold independently
of the other matrilin-3 modules (i.e., EGF-like motifs and coiled-
coil domain). However, in all cells expressing a mutation the
recombinant A-domain was retained within the cell lysate and no
protein was detected in the cell culture media. These data are
therefore in agreement with those obtained for full-length protein
and confirm that MATN3 mutations disrupt the secretion of
abnormal matrilin-3 by causing misfolding of the A-domain.
Interestingly, SDS-PAGE of cell lysates under nonreducing
conditions identified both a disulfide bonded (‘‘folded’’) A-domain
and a non-disulfide bonded (‘‘unfolded’’) intermediate. This
measurable characteristic of the expressed A-domains provided
us with the means to study further the effect of the specific
disease-causing mutations on the folding of single A-domains.
Analysis of the retained mutant A-domains demonstrated that
they existed primarily as non-disulfide bonded folding intermedi-
ates (approximately 9/1: nondisulfide/disulfide bonded). In addi-
tion disulfide bonded dimers and trimers were also detected,
suggesting a potential mechanism for the aggregation of misfolded
matrilin-3 within the rER.
In contrast, recombinant A-domain containing p.Glu252Lys, a
non-disease-causing polymorphism, was secreted in a similar
manner to normal A-domain and also had a similar proportion
of non-disulfide bonded protein in the cell lysate. This
polymorphism results in an amino acid substitution in one of the
external a-helices of the A-domain (a-7) and we hypothesize that
such a substitution is unlikely to prevent the correct folding of the
A-domain. Interestingly a recent study has reported a MED-
causing mutation (p.Phe105Ser) in the a1 helix of the matrilin-3
A-domain in one Japanese family [Mabuchi et al., 2004]. This
mutation affects a highly conserved phenylalanine residue, which
unlike Glu252 may be important for the structure and/or function
of matrilin-3. Structural and functional analysis of p.Phe105Ser
will help elucidate the role of this mutation in the pathogenesis
of MED.
Since mutant A-domains were persisting as non-disulfide
bonded (‘‘unfolded’’) intermediates we decided to examine the
role that specific chaperone proteins may play in this process
[Kuznetsov et al., 1997]. In particular we were interested in
chaperone proteins that are specifically involved in catalyzing the
formation of disulfide bonds [Clissold and Bicknell, 2003; Ferrari
and Soling, 1999]. Analysis by coimmunoprecipitation revealed
that only mutant A-domain formed a stable complex with ERp72.
ERp72 is an abundant endoplasmic reticulum protein that
contains three copies of the active site sequences of protein
disulfide isomerase and plays an important role in catalyzing the
formation of disulfide bonds [Mazzarella et al., 1990]. In addition
it has also been shown to play a key role in the unfolded protein
response (UPR) and has in fact been implicated in the retention of
misfolded COMP in the chondrocytes of pseudoachondroplasia
(PSACH) and MED patients resulting from mutations in the type
III repeats of COMP [Hecht et al., 2001]. Our data therefore
suggest that mutant A-domains experience a disruption in folding,
which hinders the formation of intrachain disulfide bonds but still
allows the formation of inappropriate interchain disulfide bonds
between other A-domains thus producing both dimers and trimers.
However we were not able to determine whether binding
of ERp72 to mutant A-domain is a cause or a consequence of
the delayed folding.
Although our initial studies were focused on understanding the
disease mechanism in vitro, the chance to study cartilage from an
MED patient with a MATN3 mutation (p.Arg121Trp) provided us
with the opportunity to confirm these findings in vivo. Analysis by
light and electron microscopy revealed the retention of protein
within the rER of chondrocytes. Furthermore immunohistochem-
istry revealed that the retained protein stained with antibodies
against matrilin-3. These data therefore confirm our in vitro
findings and suggest that MATN3 mutations result in the
misfolding of the matrilin-3 A-domain, which subsequently results
in the retention of matrilin-3 oligomers in the rER of patient
chondrocytes.
Therefore, the molecular cell pathology of MED caused by
MATN3 mutations has similarities to skeletal dysplasias caused by
mutations in the genes encoding other extracellular matrix
structural proteins, particularly PSACH and forms of MED that
result from mutations in COMP [Unger and Hecht, 2001]. In
these allelic diseases, mutations in the type III repeats of COMP
result in the persistence of an unstructured Ca
21 binding domain
[Kleerekoper et al., 2002]. These abnormal COMP molecules are
then retained within the rER of cells via the unfolded protein
response [Dinser et al., 2002]. The primary accumulation of
abnormal COMP also appears to result in the secondary retention
of type IX collagen and other proteins, eventually producing large
insoluble ‘‘inclusion bodies’’ [Vranka et al., 2001]. More recently,
Hecht et al. [2005] showed that mutant COMP can also
dramatically affect the secretion of normal matrilin-3 from
PSACH chondrocytes. This mass accumulation of protein
eventually results in cell death and a reduction in the number of
viable cells in the growth plate [Duke et al., 2003]. Interestingly a
number of chaperone proteins have been shown to be involved in
this process including ERp72 [Hecht et al., 2001; Vranka et al.,
2001].
MED is perhaps the most genetically heterogeneous of all
autosomal dominant skeletal dysplasia phenotypes and missense
mutations have now been identified in the genes encoding
HUMAN MUTATION 26(6), 557^565, 2005 563matrilin-3, COMP and type IX collagen [Briggs and Chapman,
2002; Unger and Hecht, 2001]. Recently there has been much
speculation about the reason for this genetic heterogeneity, and
a number of hypotheses have been suggested; i.e., 1) some
mutations disrupt specific interactions between matrilin-3, type IX
collagen, and COMP in the cartilage ECM [Briggs and Chapman,
2002]; 2) the blocked/delayed secretion of one mutant protein
results in a cascade of protein retention within the rER
of chondrocytes [Unger and Hecht, 2001]; or 3) a combination
of both mechanisms [Dinser et al., 2002]. In summary, our data
suggest that the retention of mutant cartilage structural protein,
within the rough endoplasmic reticulum, is a common disease
mechanism that is shared between MED resulting from either
COMP or MATN3 mutations.
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